Study on the expression of p53 and MMP‑2 in patients with lung cancer after interventional therapy

Abstract

The aim of the study was to investigate the expression of tumor suppressor gene p53 and MMP-9 in non-small cell lung cancer (NSCLC) before and after chemotherapy, and investigate its association with the effect of chemotherapy and prognosis. Fifty-eight elderly NSCLC patients comprised the observation group. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression of p53 and MMP-9 in lung cancer tissues before and after chemotherapy. Immunohistochemistry and western blot analysis were used to detect the expression of p53 and MMP-9 proteins in NSCLC tissue before and after chemotherapy. Terminal deoxynucleotidyl transferase nick end-labeling (TUNEL) was used to detect apoptotic cells. The association between the effect of chemotherapy and the expression of p53 and MMP-9 in lung cancer tissues was analysed. RT-qPCR results showed that the expression of p53 and MMP-2 mRNA in the tumor tissue after chemotherapy was significantly lower than that in the tumor tissue before chemotherapy. Western blot analysis revealed that the expression of p53 and MMP-2 protein in the tumor tissue after chemotherapy was significantly decreased. The positive expression of p53 and MMP-2 in lung cancer tissues before chemotherapy was 76.25 and 71.25%, respectively, and were reduced to 27.50 and 23.75%, respectively, after chemotherapy. After chemotherapy, the positive rates of p53 and MMP-2 were significantly lower than those before chemotherapy. TUNEL results showed that the apoptosis index increased significantly after chemotherapy. Efficiency of chemotherapy in patients with a negative expression of p53 and MMP-2 in lung cancer before chemotherapy was significantly higher than that in patients with a positive p53 and MMP-2 expression. A significant difference was found in the expression levels of p53 and MMP-2 in lung cancer before and after chemotherapy. The findings of the present study indicate that the expression levels of p53 and MMP-2 can be used as a predictor of chemotherapy sensitivity.

Correlation of TIMP1-MMP2/MMP9 Gene Expression Axis Changes with Treatment Efficacy and Survival of NSCLC Patients

“…An example is cisplatin, which is widely used in NSCLC as an adjuvant therapy. Studies on tumor tissue fragments taken from patients before the initiation of treatment with cisplatin and vinorelbine and two weeks after the end of the treatment cycle showed a statistically significant decrease in MMP2 gene expression compared to the baseline [31]. Similar results were also obtained by Liang H et al who studied the effect of the use of cisplatin on the level of expression of MMP-2 and MMP-9 proteins in a human lung cancer cell line.…”

miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2

“…Furthermore, miR-338-3p overexpression and the knockdown of MMP-2 could suppress the human neuroblastoma cell proliferation, invasion, and EMT pathway but promote the cell apoptosis. Moreover, the data of upregulated MMP-2 expression also agreed with those reported in glioblastomas and lung cancer [25,26]. Additionally, we observed that MMP-2 was directly targeted by miR-338-3p.…”